Thermoreversible Hydrogel Immunotherapy for Bladder Cancer Retention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bladder cancer, such as transurethral resection and radical cystectomy, are limited by the short residence time of immune checkpoint modulators in the bladder, leading to reduced immune activation and limited therapeutic efficacy, and systemic administration of agents like CTLA-4 antagonists is hindered by toxicity.
Innovation Solution
A combination of imiquimod or resiquimod and an immune checkpoint inhibitor, such as anti-CTLA4, is formulated in a thermoreversible hydrogel composition for local administration in the bladder, utilizing chitosan or tri-block copolymers to extend residence time and enhance immune activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint modulators are administered locally in the bladder, then the therapeutic efficacy is improved, but the residence time of the modulators is too short leading to reduced immune activation
Solution Approach 1:
A hydrogel composition acts as an intermediary carrier to deliver immune checkpoint modulators and TLR agonists to the bladder. The hydrogel provides a sustained-release matrix that maintains drug presence at the target site, resolving the contradiction between achieving therapeutic efficacy and maintaining sufficient residence time for immune activation.
Solution Approach 2:
The invention changes the physical state and release parameters of the immunomodulators by incorporating them into a hydrogel matrix. This modifies the release kinetics from rapid clearance to sustained delivery, extending residence time while maintaining therapeutic concentrations at the bladder site.
2Reliability
If CTLA-4 antagonist antibodies are administered systemically, then immune activation is enhanced, but toxicity increases limiting their application
Solution Approach 1:
The invention applies local quality by delivering CTLA-4 antagonist antibodies specifically to the bladder site through the hydrogel formulation. This localized delivery enhances immune activation at the tumor site while minimizing systemic exposure and associated toxicity, resolving the contradiction between immune activation efficacy and toxicity.
Solution Approach 2:
By formulating the antibody in a locally-administered hydrogel rather than systemic injection, the treatment achieves high local concentration for immune activation while keeping systemic circulation levels low, thereby reducing toxicity.
3Reliability
If combinations of immunomodulating compositions are used to activate innate and adaptive immunity, then therapeutic benefit is improved, but complexity of the treatment increases
Solution Approach 1:
The invention merges multiple immunomodulating agents (CTLA-4 antagonist antibody and TLR agonist) into a single hydrogel formulation. This combination approach delivers both innate (TLR agonist) and adaptive (antibody) immunity activators simultaneously from one administration, improving therapeutic benefit while managing complexity through unified delivery.
Solution Approach 2:
The hydrogel composition serves as a universal delivery platform that can accommodate multiple different immunomodulating agents with different properties (antibodies, small molecules, nucleic acids). This multi-functional approach allows combination therapy without proportionally increasing administrative complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogel-based formulation prolongs the duration of immune modulators in the bladder, enhancing immune response and improving treatment outcomes for bladder cancer, including increased tumor reduction and survival rates.
Implementation Method 1
a thermoreversible hydrogel composition for local administration in the bladder
Implementation Method 2
The thermoreversible hydrogel composition comprises chitosan or at least one tri block copolymer having a general formula ABA or BAB copolymer, wherein A is a hydrophilic block and B is a hydrophobic block
Data Source
Figure 1~2
Figure 3A
Figure 3B
AI summary
The invention relates to a combination medicament for use in treatment of a cancer of an internal body cavity. The combination medicament comprises a TLR agonist formulated for local administration in a thermo-reversible hydrogel composition, and an immune checkpoint inhibitor selected from the group consisting of an anti-PD1, anti-PDL1, and anti-CTLA4, formulated for local administration in a thermo-reversible hydrogel composition.